On the first trading day of January, the company announced that a combination of itacitinib and corticosteroids failed to meet the primary and secondary endpoints in a phase 3 trial in treatment-naive acute graft-versus-host disease (GVHD).Management expects the drug to deliver roughly $1.9 billion in product revenue for the year -- more than enough to fund research and development and generate operating income.